Emerging synthetic cannabinoids detected by a drug checking service in Toronto, Canada. (3rd August 2022)

• Record Type: Journal Article
• Authors: Scarfone, K. M.; Maghsoudi, N.; McDonald, K.; Thompson, H.; Stefan, C.; Beriault, D. R.; Werb, D.; Bowles, J. M.
• Is Part Of: Clinical toxicology. Volume 60:Number 8(2022)
• Page Start: 979
• Page End: 984
• Publication Date: 2022-08-03
• Subjects: CNS/psychological -- complications of poisoning -- opioids -- analgesics -- pharmaceuticals; Toxicology -- Periodicals; Toxicological emergencies -- Periodicals; 615.9
• DOI: 10.1080/15563650.2022.2069575
• Languages: English
• ISSNs: 1556-3650

Abstract

Abstract: Background: Toronto's Drug Checking Service (DCS) provides people who use drugs with information on the chemical composition of their substances and conducts real-time monitoring of the unregulated drug supply. Presented are first known data of three newly detected synthetic cannabinoids (SCs) in Toronto, Ontario. Methods: The present data are from samples analyzed between April and November 2020. Samples were collected at partnering harm reduction agencies in Toronto and analyzed using gas or liquid chromatography-mass spectrometry. An intake survey queried about the sample characteristics on submission, including expected drug(s). Results: Samples were analyzed between 1 April and 20 November 2020 ( N = 19), which marks the period immediately following imposed COVID-19 border and movement restrictions in Canada. The newly detected, unexpected SCs were ACHMINACA ( n = 15), AB-FUBINACA ( n = 3), and 4-fluoro-MDMB-BUTINACA ( n = 1). Fentanyl was expected in 74% ( n = 14). Most SCs were detected in samples containing fentanyl or related analogues ( n = 18; 95%), or benzodiazepine-related drugs (i.e., etizolam and flualprazolam) ( n = 15; 79%). Conclusions: This information can inform overdose prevention efforts and drug market monitoring of SCs in Toronto and regions served by the same drug trafficking routes. The detection of SCs during a period marked by COVID-19-related restrictions can contribute to efforts to identify global drug market trends during this time.